Equities analysts expect that Bio-Path Holdings, Inc. (NASDAQ:BPTH) will post earnings per share of ($0.02) for the current quarter, according to Zacks. Zero analysts have made estimates for Bio-Path Holdings’ earnings. Bio-Path Holdings reported earnings per share of ($0.01) during the same quarter last year, which would indicate a negative year over year growth rate of 100%. The business is expected to announce its next quarterly earnings results on Wednesday, March 21st.

According to Zacks, analysts expect that Bio-Path Holdings will report full year earnings of ($0.08) per share for the current financial year. For the next financial year, analysts expect that the firm will post earnings of ($0.09) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Bio-Path Holdings.

Bio-Path Holdings (NASDAQ:BPTH) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($0.02) EPS for the quarter, hitting analysts’ consensus estimates of ($0.02).

BPTH has been the subject of a number of recent research reports. HC Wainwright set a $5.00 price objective on Bio-Path Holdings and gave the stock a “buy” rating in a report on Friday, August 11th. ValuEngine lowered Bio-Path Holdings from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Finally, decreased their price objective on Bio-Path Holdings from $4.50 to $1.50 and set a “buy” rating for the company in a report on Wednesday, November 15th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $1.67.

Shares of Bio-Path Holdings (NASDAQ BPTH) opened at $0.31 on Monday. Bio-Path Holdings has a twelve month low of $0.25 and a twelve month high of $1.38.

WARNING: “Analysts Anticipate Bio-Path Holdings, Inc. (BPTH) Will Post Earnings of -$0.02 Per Share” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/20/analysts-anticipate-bio-path-holdings-inc-bpth-will-post-earnings-of-0-02-per-share.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. HighTower Advisors LLC boosted its stake in shares of Bio-Path Holdings by 0.3% in the 2nd quarter. HighTower Advisors LLC now owns 1,267,070 shares of the company’s stock worth $492,000 after buying an additional 4,000 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Bio-Path Holdings by 1.7% in the 1st quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock worth $257,000 after buying an additional 5,172 shares during the last quarter. Sabby Management LLC boosted its stake in shares of Bio-Path Holdings by 73.2% in the 2nd quarter. Sabby Management LLC now owns 1,190,886 shares of the company’s stock worth $462,000 after buying an additional 503,488 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of Bio-Path Holdings by 5,474.3% in the 2nd quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock worth $681,000 after buying an additional 1,741,978 shares during the last quarter. Hedge funds and other institutional investors own 11.57% of the company’s stock.

Bio-Path Holdings Company Profile

Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.

Get a free copy of the Zacks research report on Bio-Path Holdings (BPTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related stocks with our FREE daily email newsletter.